This is a working overview of GW501516, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-01 and is reviewed periodically as new material appears.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
=== August === 1 August Tony Brien, 54, footballer (Leicester City, Chesterfield, Rotherham United, West Bromwich Albion, Mansfield Town, Chester City, Hull City). John Madigan, 76, hurler (Charleville, Avondhu) and rugby union player (UL Bohemians, Munster). 4 August – Colin O'Daly, 70, chef. 9 August – Art McRory, 82, Gaelic footballer (Dungannon, Tyrone senior team) and manager (Tyrone minor and senior teams). Born in Northern Ireland. 15 August – Liam McDaid, 78, Roman Catholic prelate. 23 August – Chryss Goulandris, 73, businesswoman, horse breeder and wife of Tony O'Reilly. Born in the United States.
KSM = KSW/ KMW As can be observed from Figure 1, KMW is independent of any effects from the stationary phase, assuming the same micellar mobile phase. The validity of the retention mechanism proposed by Armstrong and Nome has been successfully, and repeated confirmed experimentally. However, some variations and alternate theories have also been proposed. Jandera and Fischer developed equations to describe the dependence of retention behavior on the change in micellar concentrations. They found that the retention of most compounds tested decreased with increasing concentrations of micelles. From this, it can be surmised that the compounds associate with the micelles as they spend less time associated with the stationary phase. Foley proposed a similar retentive model to that of Armstrong and Nome which was a general model for secondary chemical equilibria in liquid chromatography. While this model was developed in a previous reference, and could be used for any secondary chemical equilibria such as acid-base equilibria, and ion-pairing, Foley further refined the model for MLC. When an equilibrant (X), in this case surfactant, is added to the mobile phase, a secondary equilibria is created in which an analyte will exist as free analyte (A), and complexed with the equilibrant (AX). The two forms will be retained by the stationary phase to different extents, thus allowing the retention to be varied by adjusting the concentration of equilibrant (micelles).
I am so relieved. I can't even believe it. Exactly two years ago I was forced to have as much security as possible due to threats. Ever since then, i have never walked alone in the streets. It was heavy. Fortunately, I could still do my job. It was a difficult time in my career. When you hear such news, it is an incredible relief. In 2017, writer Raf Sauviller published his book Borgerokko Maffia, which was distributed to many libraries across Flanders (Belgium) and the Netherlands. In his book, he discusses the corruption that takes place in the Port of Antwerp amongst police officers and Customs controls. According to research which was carried out in 2018, the municipality of Borgerhout, Antwerp, had an illegal economy which was larger than the regular economy due to the influx of funds by the Moroccan mafia. During an interview by the newspaper De Morgen on the context of this book, the mayor of Antwerp, Bart De Wever, admitted that there were many difficulties on intercepting the main commanders of the Moroccan mafia in Antwerp. He also stated:
== Data analysis == CyTOF mass cytometry data is recorded in tables that list, for each cell, the signal detected per channel, which is proportional to the number of antibodies tagged with the corresponding channel's isotope bound to that cell. These data are formatted as FCS files, which are compatible with traditional flow cytometry software. Due to the high-dimensional nature of mass cytometry data, novel data analysis tools have been developed as well. Imaging Mass Cytometry data analysis has its specificity due to different nature of data obtained. In terms of data analysis, both IMC and CyTOF generate large datasets with high dimensionality that require specialized computational methods for analysis. However, data generated by IMC can be more challenging to analyze due to additional data complexity and need for specific tools and pipelines specific for digital image analysis, whereas the data generated by CyTOF is generally analyzed using conventional flow cytometry software. A comprehensive overview of IMC data analysis techniques has been given by Milosevic in.
Sources: en.wikipedia.org
== Deaths == 1 January – Frank McGarvey, Scottish footballer (St Mirren, Celtic, national team) (b. 1956) 18 March – Robert Lindsay, 29th Earl of Crawford, Scottish peer, MP (1955–1974) and Minister of State for Defence (1970–1972) (b. 1927) 21 March Willie Bell, Scottish footballer (Leeds United, national team) and manager (Birmingham City) (b. 1937) John Smith, Baron Kirkhill, Scottish peer, Lord Provost of Aberdeen (1971–1975) and Minister of State for Scotland (1975–1978) (b. 1930) 1 April – Ken Buchanan, professional boxer who became undisputed world lightweight champion in 1971 (b. 1945) 8 April – Bob Heatlie, Scottish songwriter ("Japanese Boy", "Cry Just a Little Bit", "Merry Christmas Everyone") and record producer (b. 1946). 30 April – Elizabeth Scott, Duchess of Buccleuch, wife of Richard Scott, 10th Duke of Buccleuch (b. 1954) 10 May – Hugo Burge, internet entrepreneur and owner of Marchmont House (b. 1972) 15 June – Gordon McQueen, Scottish footballer (Leeds United, Manchester United, national team) and manager. (b. 1953) 21 June – Winnie Ewing, Scottish politician (MP (1967–1979), MEP (1979–1999), MSP (1999–2003), President of the Scottish National Party (1987–2005)) (b. 1929) 26 June Craig Brown, Scottish professional footballer and football manager. (b. 1940) David Ogilvy, 13th Earl of Airlie, Scottish peer and Lord Chamberlain (1984–1997) (b. 1926) 2 July – Greig Oliver, 58, rugby union player. 6 September – John Cairney, Scottish actor (A Night to Remember, Cleopatra, Jason and the Argonauts), author and painter. (b.
k¢ is the capacity factor of the solute KSW is the partition coefficient of the solute between the stationary phase and the water KMW is the partition coefficient of the solute between the micelles and the water f is the phase volume ratio (stationary phase volume/mobile phase volume) n is the molar volume of the surfactant CM is the concentration of the micelle in the mobile phase (total surfactant concentration - critical micelle concentration) A plot of 1/k¢ verses CM gives a straight line in which KSW can be calculated from the intercept and KMW can be obtained from the ratio of the slope to the intercept. Finally, KSM can be obtained from the ratio of the other two partition coefficients:
Most children with progeria appear normal at birth and during early infancy. Children with progeria usually develop the first symptoms during their first few months of life. The earliest symptoms may include a failure to thrive and a localized scleroderma-like skin condition. As a child ages past infancy, additional conditions become apparent, usually around 18–24 months. Limited growth, full-body alopecia (hair loss), and a distinctive appearance (a small face with a shallow, recessed jaw and a pinched nose) are all characteristics of progeria. Signs and symptoms of this progressive disease tend to become more marked as the child ages. Later, the condition causes wrinkled skin, kidney failure, loss of eyesight, and atherosclerosis and other cardiovascular problems. Scleroderma, a hardening and tightening of the skin on trunk and extremities of the body, is prevalent. People diagnosed with this disorder usually have small, fragile bodies, like those of older adults. The head is usually large relative to the body, with a narrow, wrinkled face and a beak nose. Prominent scalp veins are noticeable (made more obvious by alopecia), as well as prominent eyes. Musculoskeletal degeneration causes loss of body fat and muscle, stiff joints, hip dislocations, and other symptoms generally absent in the non-elderly population. Individuals usually retain typical mental and motor function.
== Toxicity == Sometimes, the potential or real toxicity of the compound is taken into account (ADME-Tox or ADMET). Parameters used to characterize toxicity include the median lethal dose (LD50) and therapeutic index. Computational chemists try to predict the ADME-Tox qualities of compounds through methods like QSPR or QSAR. The route of administration critically influences ADME.
== Euthanasia protocol == Lethal injection has also been used in cases of euthanasia to facilitate voluntary death in patients with terminal or chronically painful conditions. Euthanasia can be accomplished either through oral, intravenous, or intramuscular administration of drugs. In individuals who are incapable of swallowing lethal doses of medication, an intravenous route is preferred because it is the most reliable and rapid way to accomplish euthanasia. The following is a Dutch protocol for parenteral (intravenous) administration to obtain euthanasia, with the old protocol listed first and the new protocol listed second:
Sources: en.wikipedia.org
== History == The toxin was first described in detail in 1969 by two Brazilian researchers from University of Campinas, Júlia Prado-Franceschi and Oswaldo Vital-Brazil. The snake C-type lectin convulxin was reported to activate platelets in a similar way to collagen in the late 1970s, but this was only announced after the discovery of the association with the FcR γ-chain and after it was recognized to mediate activation through GPVI. Now this toxin is widely used to study mammalian platelet receptors.
Doxycycline, sold under the brand names Vibramycin and Doryx, among others, is a broad-spectrum antibiotic of the tetracycline class used in the treatment of infections caused by bacteria and certain parasites. It is used to treat bacterial pneumonia, acne, chlamydia infections, Lyme disease, cholera, typhus, and syphilis, and is sometimes used to prevent malaria. Doxycycline may be taken by mouth or intravenously. Common side effects include diarrhea, nausea, vomiting, abdominal pain, and an increased risk of sunburn. Use during pregnancy is not recommended. Doxycycline can be used in children of all ages, including for Lyme disease and rickettsial infections. Like other agents of the tetracycline class, it slows or kills bacteria by inhibiting protein production. It kills Plasmodium—microorganisms associated with malaria—by targeting a plastid organelle, the apicoplast. Doxycycline post-exposure prophylaxis (doxyPEP) is also used to prevent sexually transmitted infections, particularly when skin or fluid contact has occurred, such as if protection was not used in men who have sex with men, and is supported by CDC guidelines.
Anterior pituitary In the hypothalamic–adenohypophyseal axis, releasing hormones, also known as hypophysiotropic or hypothalamic hormones, are released from the median eminence, a prolongation of the hypothalamus, into the hypophyseal portal system, which carries them to the anterior pituitary where they exert their regulatory functions on the secretion of adenohypophyseal hormones. These hypophysiotropic hormones are stimulated by parvocellular neurosecretory cells located in the periventricular area of the hypothalamus. After their release into the capillaries of the third ventricle, the hypophysiotropic hormones travel through what is known as the hypothalamo-pituitary portal circulation. Once they reach their destination in the anterior pituitary, these hormones bind to specific receptors located on the surface of pituitary cells. Depending on which cells are activated through this binding, the pituitary will either begin secreting or stop secreting hormones into the rest of the bloodstream.
=== Hypothalamus === Temperature is regulated in the hypothalamus. The trigger of a fever, called a pyrogen, results in the release of prostaglandin E2 (PGE2). PGE2 in turn acts on the hypothalamus, which creates a systemic response in the body, causing heat-generating effects to match a new higher temperature set point. There are four receptors in which PGE2 can bind (EP1-4), with a previous study showing the EP3 subtype is what mediates the fever response. Hence, the hypothalamus can be seen as working like a thermostat. When the set point is raised, the body increases its temperature through both active generation of heat and retention of heat. Peripheral vasoconstriction both reduces heat loss through the skin and causes the person to feel cold. Norepinephrine increases thermogenesis in brown adipose tissue, and muscle contraction through shivering raises the metabolic rate. If these measures are insufficient to make the blood temperature in the brain match the new set point in the hypothalamus, the brain orchestrates heat effector mechanisms via the autonomic nervous system or primary motor center for shivering. These may be:
== Medical uses == Hyaluronic acid has been FDA-approved to treat osteoarthritis of the knee via intra-articular injection. A 2012 review showed that the quality of studies supporting this use was mostly poor, with a general absence of significant benefits, and that intra-articular injection of HA could possibly cause adverse effects. A 2020 meta-analysis found that intra-articular injection of high molecular weight HA improved both pain and function in people with knee osteoarthritis. Hyaluronic acid has been used to treat dry eye. Hyaluronic acid is a common ingredient in skin care products. Hyaluronic acid is used as a dermal filler in cosmetic surgery. It is typically injected using either a classic sharp hypodermic needle or a micro-cannula. Hyaluronic acid may be used as a soft tissue filler, including to separate tissues exposed to radiation for prostate cancer. Complications may involve injury to nerves and microvessels, pain, and bruising, with possible side effects including erythema, itching, and vascular occlusion. In some cases, hyaluronic acid fillers can result in a granulomatous foreign body reaction.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.